NCT07529002Recruiting
Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors
Source: ClinicalTrials.gov · Last updated 14 Apr 2026
Brief summary (registry, in English)
This project is driven by clinical needs and focuses on the mucin (MUC) family, key glycopeptide antigens involved in mediating immune evasion in solid tumors. We selected multiple members of this family as research subjects. Based on the MUC18 target, we developed the probe ⁸⁹Zr-SS-CNB001 (HuAA98-14, hereafter referred to as ⁸⁹Zr-s-C1). Studies have demonstrated that ⁸⁹Zr-s-C1 PET/CT enables noninvasive in vivo identification of tumor lesions in patients with solid tumors, and its imaging efficacy positively correlates with MUC18 expression levels in the patient's tumor tissue.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 20 (estimated)
- First submitted
- 20 Mar 2026
- Start date
- 14 Apr 2026
- Primary completion date
- 1 Mar 2028
- Lead sponsor
- Peking University Cancer Hospital & Institute
- Diseases
- Childhood cancers
- NCT number
- NCT07529002
What you commit to
- Study type: Observational
- Planned participants: 20
- From 14 Apr 2026 to the primary completion date, 1 Mar 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Case inclusion criteria
- Patients with pathologically confirmed newly diagnosed solid tumors (such as melanoma, gastric cancer, colorectal cancer, etc.), or those with recent recurrence or suspected recurrence of previous solid tumors. Both male and female patients are eligible.
- Hematology, liver, and kidney function meeting the following criteria:
- Hematology: WBC ≥ 4.0×10⁹/L or neutrophil count ≥ 1.5×10⁹/L, PLT ≥ 100×10⁹/L, Hb ≥ 90 g/L; PT or APTT ≤ 1.5 × ULN.
- Liver and kidney function: T-Bil ≤ 1.5 × ULN, ALT and AST ≤ 2.5 × ULN (or ≤ 5 × ULN for subjects with liver metastases), ALP ≤ 2.5 × ULN (if bone or liver metastases are present, ALP ≤ 4.5 × ULN); BUN ≤ 1.5 × ULN, SCr ≤ 1.5 × ULN.
- Expected survival ≥ 12 weeks.
- Good compliance with follow-up.
- Presence of at least one measurable target lesion according to RECIST 1.1 criteria.
- Female subjects must use effective contraception (effective contraception refers to sterilization, intrauterine hormone devices, condoms, contraceptive pills/agents, abstinence, or vasectomized partner) during the study and for 6 months after the study ends; male subjects must agree to use contraception during the study and for 6 months after the study ends.
- Subjects must fully understand and voluntarily participate in this trial, and sign the Informed Consent Form.
- Case exclusion criteria
- Severe liver and kidney dysfunction.
- Women preparing for pregnancy, pregnant, or breastfeeding.
- Inability to lie flat for half an hour.
- Inability to provide informed consent.
- Suffering from claustrophobia or other psychiatric disorders.
- Known allergy to the investigational drug or its excipients.
- Other situations deemed unsuitable for trial participation by the researchers.
Age in the registry: 15 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing cancer hosipitaal Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.